Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Neoplasms of the CNS

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 32 articles:
HTML format



Single Articles


    August 2021
  1. HILBERS ML, Dimitriou F, Lau P, Bhave P, et al
    Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Eur J Cancer. 2021;156:149-163.
    PubMed     Abstract available


  2. LOMBARDI G, Del Bianco P, Brandes AA, Eoli M, et al
    Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
    Eur J Cancer. 2021;155:179-190.
    PubMed     Abstract available


    April 2021
  3. VERBRUGGEN LC, Kok JL, Teepen JC, Janssens GO, et al
    Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER study.
    Eur J Cancer. 2021;150:240-249.
    PubMed     Abstract available


  4. DIMITRIOU F, Zaremba A, Allayous C, Kahler KC, et al
    Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Eur J Cancer. 2021;149:37-48.
    PubMed     Abstract available


  5. KARSCHNIA P, Vogelbaum MA, van den Bent M, Cahill DP, et al
    Evidence-based recommendations on categories for extent of resection in diffuse glioma.
    Eur J Cancer. 2021;149:23-33.
    PubMed     Abstract available


    March 2021
  6. PARTANEN M, Anghelescu DL, Hall L, Schreiber JE, et al
    Longitudinal associations between exposure to anesthesia and neurocognitive functioning in pediatric medulloblastoma.
    Eur J Cancer. 2021;148:103-111.
    PubMed     Abstract available


    February 2021
  7. GRAMATZKI D, Felsberg J, Hentschel B, Wolter M, et al
    Telomerase reverse transcriptase promoter mutation- and O(6)-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Eur J Cancer. 2021;147:84-94.
    PubMed     Abstract available


  8. CLEMENT PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, et al
    Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Eur J Cancer. 2021;147:1-12.
    PubMed     Abstract available


  9. BERLANGA P, Pasqualini C, Potschger U, Sanguesa C, et al
    Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
    Eur J Cancer. 2021;144:1-8.
    PubMed     Abstract available


    January 2021
  10. TOSONI A, Gatto L, Franceschi E, Di Nunno V, et al
    Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study.
    Eur J Cancer. 2021;145:171-178.
    PubMed     Abstract available


    December 2020
  11. CARAMANNA I, Bottomley A, Drijver AJ, Twisk J, et al
    Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
    Eur J Cancer. 2020;144:162-168.
    PubMed     Abstract available


    November 2020
  12. HONG AM, Waldstein C, Shivalingam B, Carlino MS, et al
    Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.
    Eur J Cancer. 2020;142:10-17.
    PubMed     Abstract available


    October 2020
  13. RAUSCHENBACH L, Wieland A, Reinartz R, Kebir S, et al
    Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
    Eur J Cancer. 2020;140:130-139.
    PubMed     Abstract available


    September 2020
  14. MORENO L, Barone G, DuBois SG, Molenaar J, et al
    Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Eur J Cancer. 2020;136:52-68.
    PubMed     Abstract available


    July 2020
  15. FRANCESCHI E, Tosoni A, Bartolini S, Minichillo S, et al
    Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.
    Eur J Cancer. 2020;137:10-17.
    PubMed     Abstract available


  16. CALLEC L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, et al
    Relapsing intracranial germ cell tumours warrant retreatment.
    Eur J Cancer. 2020;136:186-194.
    PubMed     Abstract available


    June 2020
  17. BERGHOFF AS, Wippel C, Starzer AM, Ballarini N, et al
    Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer.
    Eur J Cancer. 2020;135:150-158.
    PubMed     Abstract available


  18. CARRON R, Gaudy-Marqueste C, Amatore F, Padovani L, et al
    Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.
    Eur J Cancer. 2020;135:52-61.
    PubMed     Abstract available


    May 2020
  19. WOLPERT F, Berghoff AS, Grossenbacher B, Lareida A, et al
    Venous thromboembolic events in patients with brain metastases: the PICOS score.
    Eur J Cancer. 2020;134:75-85.
    PubMed     Abstract available


  20. PAGE S, Milner-Watts C, Perna M, Janzic U, et al
    Systemic treatment of brain metastases in non-small cell lung cancer.
    Eur J Cancer. 2020;132:187-198.
    PubMed     Abstract available


    April 2020
  21. TSAKONAS G, Lewensohn R, Botling J, Ortiz-Villalon C, et al
    An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
    Eur J Cancer. 2020;132:24-34.
    PubMed     Abstract available


    March 2020
  22. CREED JH, Smith-Warner SA, Gerke TA, Egan KM, et al
    A prospective study of coffee and tea consumption and the risk of glioma in the UK Biobank.
    Eur J Cancer. 2020;129:123-131.
    PubMed     Abstract available


  23. DELUCHE E, Antoine A, Bachelot T, Lardy-Cleaud A, et al
    Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Eur J Cancer. 2020;129:60-70.
    PubMed     Abstract available


    January 2020
  24. ACKER G, Zollfrank J, Jelgersma C, Nieminen-Kelha M, et al
    The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.
    Eur J Cancer. 2020;126:106-115.
    PubMed     Abstract available


    December 2019
  25. PASQUIER D, Darlix A, Louvel G, Fraisse J, et al
    Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
    Eur J Cancer. 2019;125:22-30.
    PubMed     Abstract available


    October 2019
  26. GROSSI F, Genova C, Crino L, Delmonte A, et al
    Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Eur J Cancer. 2019;123:72-80.
    PubMed     Abstract available


  27. HENDRIKS LEL, Dooms C, Berghmans T, Novello S, et al
    Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.
    Eur J Cancer. 2019;123:28-35.
    PubMed     Abstract available


    September 2019
  28. JIANG T, Zhang Y, Li X, Zhao C, et al
    EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Eur J Cancer. 2019;121:98-108.
    PubMed     Abstract available


  29. LLUCH A, Gonzalez-Angulo AM, Casadevall D, Eterovic AK, et al
    Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
    Eur J Cancer. 2019;120:54-64.
    PubMed     Abstract available


    August 2019
  30. CHANG LC, Lim CK, Chang LY, Chen KY, et al
    Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Eur J Cancer. 2019;119:77-86.
    PubMed     Abstract available


    June 2019
  31. HENDRIKS LEL, Bootsma G, Mourlanette J, Henon C, et al
    Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Eur J Cancer. 2019;116:182-189.
    PubMed     Abstract available


    January 2019
  32. MONTEMURRO F, Ellis P, Anton A, Wuerstlein R, et al
    Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
    Eur J Cancer. 2019;109:92-102.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: